Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stake Boosted by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 32.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,383 shares of the company’s stock after acquiring an additional 7,441 shares during the period. The Manufacturers Life Insurance Company’s holdings in Nurix Therapeutics were worth $683,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Amalgamated Bank lifted its stake in Nurix Therapeutics by 30.6% in the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after acquiring an additional 511 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Nurix Therapeutics by 31.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after purchasing an additional 559 shares in the last quarter. International Assets Investment Management LLC lifted its stake in shares of Nurix Therapeutics by 1,098.4% in the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after purchasing an additional 4,119 shares during the last quarter. Quest Partners LLC boosted its holdings in Nurix Therapeutics by 21.3% in the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock worth $168,000 after purchasing an additional 1,312 shares in the last quarter. Finally, Dark Forest Capital Management LP acquired a new position in Nurix Therapeutics during the second quarter worth $201,000.

Insider Activity at Nurix Therapeutics

In related news, insider Christine Ring sold 5,760 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $22.23, for a total value of $128,044.80. Following the sale, the insider now owns 24,592 shares of the company’s stock, valued at $546,680.16. The trade was a 18.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Houte Hans Van sold 3,546 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $24.28, for a total transaction of $86,096.88. Following the transaction, the chief financial officer now owns 33,724 shares of the company’s stock, valued at approximately $818,818.72. This represents a 9.51 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,401 shares of company stock worth $437,453. 7.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on NRIX shares. UBS Group assumed coverage on Nurix Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $35.00 price target for the company. Robert W. Baird assumed coverage on Nurix Therapeutics in a report on Friday, September 6th. They issued an “outperform” rating and a $26.00 target price for the company. HC Wainwright increased their price target on Nurix Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday. Needham & Company LLC restated a “buy” rating and issued a $29.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday. Finally, Royal Bank of Canada lowered their target price on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $30.35.

Nurix Therapeutics Stock Performance

Shares of NRIX opened at $20.27 on Friday. The company has a 50-day simple moving average of $23.64 and a 200-day simple moving average of $22.12. Nurix Therapeutics, Inc. has a 52 week low of $7.65 and a 52 week high of $29.56. The firm has a market capitalization of $1.44 billion, a P/E ratio of -6.97 and a beta of 2.11.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Friday, October 11th. The company reported ($0.67) EPS for the quarter, meeting the consensus estimate of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The firm had revenue of $12.59 million during the quarter, compared to analysts’ expectations of $13.85 million. As a group, equities analysts forecast that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.